eMERGE Northwestern Group

Ovarian/Uterine Cancer (OvUtCa)

The KPWA/UW-led ovarian/uterine cancer phenotype has been validated at Mayo Clinic, the secondary phenotype development site. Validation results at both the primary and secondary sites were strong and the phenotype is ready for network wide implementation. The pseudo code document posted 11/30/2017 is correct as is and should be used by network sites for phenotype implementation. A validated data dictionary of covariates for this phenotype will be added to PheKB by 2/15/2018, but sites are encouraged to begin implementing the phenotype algorithm now.

Owner Phenotyping Groups:

eMERGE GHC/University of Washington Group

View Phenotyping Groups:

eMERGE CCHMC Group

eMERGE CCHMC/BCH Group

eMERGE CHOP Group

eMERGE Columbia Group

eMERGE Geisinger Group

eMERGE GHC/University of Washington Group

eMERGE Harvard Group

eMERGE Marshfield Group

eMERGE Mayo Group

eMERGE Meharry Group

eMERGE Mount Sinai Group

eMERGE Northwestern Group

eMERGE Phenotype WG

eMERGE Vanderbilt Group

Final

PhEMA BPH (Benign Prostatic Hyperplasia) cases

This is PhEMA (Phenotype Execution Modeling Architecture, projectphema.org)'s implementation of the following BPH (Benign Prostatic Hyperplasia) case algorithm from the following BPH case and control algorithm on PheKB:

https://phekb.org/phenotype/benign-prostatic-hyperplasia-bph

Artifacts for this phenotype, inc. an HQMF representation, a KNIME workflow that can run against an i2b2 instance, and a snapshot of the PhAT graphical representation, are posted on GitHub:

Owner Phenotyping Groups:

eMERGE Northwestern Group

eMERGE Vanderbilt Group

PheMA Test Group

View Phenotyping Groups:

eMERGE Columbia Group

eMERGE Geisinger Group

eMERGE Harvard Group

eMERGE Marshfield Group

eMERGE Mayo Group

eMERGE Northwestern Group

eMERGE Phenotype WG

eMERGE Vanderbilt Group

Final

SLE (Systemic Lupus Erythematosus) using SLICC (Systemic Lupus Internation Collaborating Clinics) Criteria

Systemic Lupus Erythematosus (SLE) is a chronic, systemic autoimmune disease that can affect many parts of the body including skin, lungs, brain, heart, kidneys, joints, and blood vessels. SLE presentation can vary significantly between patients. Because of this, it can be challenging to identify a patient as having SLE. Between 300,000 and 2,000,000 people in the US are estimated to have SLE. Determination of an exact number of people affected is challenging as the disease is difficult to identify given the diverse presentations and the length of time it may take for symptoms to appear.

Owner Phenotyping Groups:

eMERGE Northwestern Group

View Phenotyping Groups:

eMERGE Mayo Group

eMERGE Phenotype WG

Final

Type 2 Diabetes Mellitus

This describes the Northwestern University Type 2 diabetes mellitus (T2DM) algorithms for extracting both T2DM cases and T2DM controls from the electronic medical record (EMR). Comprehensive documentation of the algorithms can be found

Owner Phenotyping Groups:

eMERGE Northwestern Group

View Phenotyping Groups:

eMERGE Phenotype WG

Final

Type1 or Type 2 Diabetes Mellitus

Phenotyping algorithm for the identification of patients with type 1 or type 2 diabetes mellitus (DM) preoperatively using routinely available clinical data from electronic
health records.

View Phenotyping Groups:

American-Swiss Allergy Phenotyping Group

BioVU Phenotyping

Clostridium Difficile Colitis Phenotype Group

Denny’s Group at Vandy

eMERGE CCHMC Group

eMERGE CCHMC/BCH Group

eMERGE CHOP Group

eMERGE Columbia Group

eMERGE Geisinger Group

eMERGE GHC/University of Washington Group

eMERGE Harvard Group